Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

The Cardiovascular Disease Pipeline: A Strategic Review

Published by: Decision Resources

Published: Apr. 27, 2009 - 30 Pages


Table of Contents


Executive Summary

Strategic Considerations
Stakeholder Implications

Introduction

The Cardiovascular Disease Pipeline

Emerging Agents Target Unmet Needs

Notable Players in the Cardiovascular Disease Sector

Companies Leading the Cardiovascular Disease Market Have Much to Lose
Merck

Solvay

Key Areas of Opportunity in the Cardiovascular Disease Pipeline

Combination Drugs

The Anticoagulant Market

Outlook: Can Emerging Agents Mitigate Generic Erosion?

Current Market Statistics

Challenges and Opportunities for Emerging Agents

Tables

1. Cardiovascular Diseases: Definitions and Common Drug Class Treatments

2. Drug Classes Commonly Prescribed to Treat Cardiovascular Disease

3. Market-Leading Companies, 2008

4. Merck’s Cardiovascular Pipeline

5. Solvay’s Cardiovascular Pipeline

6. Fixed-Dose Combination Agents in Clinical Development

7. Anticoagulants in Clinical Development

8. Top-Selling Cardiovascular Drugs, 2008

9. Key Patent Expiries for Market-Leading Companies

Figures

1. Cardiovascular Pipeline by Development Phase

2. Cardiovascular Pipeline by Disease

3. Late-Stage Development Agents, Chronic Versus Acute Therapies

4. Development Activity, by Company Size

5. Leading Cardiovascular Pipelines, by Number of Agents

6. Leading Cardiovascular Pipelines: Number of Agents by Disease

7. Pfizer Cardiovascular Franchise Sales, 2008

8. Sanofi-Aventis Cardiovascular Franchise Sales, 2008

9. Merck Cardiovascular Sales, 2003-2008

10. Cardiovascular Disease Market Growth, 2003-2008

11. Worldwide Sales of Cardiovascular Drug Classes, 2008

12. Cardiovascular Disease Market Growth by Region, 2003-2008

Abstract

Introduction

The robust and diverse cardiovascular disease (CVD) R&D pipeline is evidence of companies’awareness that these diseases remain leading causes of death worldwide, and that the chronic nature of many CVDs offers significant commercial opportunity. Drug developers have populated their pipelines with novel approaches and new mechanisms of action that seek to fulfill unmet needs and tap remaining therapeutic opportunities. This pipeline activity, combined with the generic entry of current market-leading agents, will help to establish new leaders in the cardiovascular market.

Get the Answers You Need to Shape Your Strategy
  • The CVD market has experienced strong growth thanks to the emergence of efficacious drug classes to treat chronic conditions. What is the size of the CVD market? What are the leading drug classes and agents? Which companies hold the greatest market share?
  • The high CVD mortality rate signals the need for more-efficacious treatments. Which companies are developing new CVD treatments? Which diseases are primary focuses of development?
    • Will emerging agents establish a new market leader?
  • An abundance of generic CVD agents challenges the uptake of novel treatments. What opportunities remain in the CVD market? How can drug developers maximize their chances of success?
Scope
  • 2008 market: 2008 sales; leading drug classes; market-leading companies; commercial position of leading agents.
  • The cardiovascular disease pipeline: Number of agents in development; disease focus; active companies; profiles of Merck and Solvay.
  • Opportunities in cardiovascular disease: Fixed-dose combinations; growth of the anticoagulant market.
  • Outlook: Impact of generic erosion; outlook to 2014; impact of the Merck/Schering-Plough merger.
Diseases Mentioned in This Spectrum Report
  • Acute coronary syndrome
  • Acute heart failure
  • Atrial fibrillation
  • Chronic heart failure
  • Coronary heart disease
  • Dyslipidemia
  • Hypertension
  • Post-myocardial infarction
  • Venous thromboembolism


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009